Panacea Biotec Limited – Q1 FY26 Results Summary
Announcement Date: August 14, 2025

Financial Highlights (₹ Lakh):

• Standalone Revenue: ₹11,225 (Q1 FY26) vs ₹5,688 (Q1 FY25), up 97.3% YoY
• Consolidated Revenue: ₹16,670 (Q1 FY26) vs ₹11,572 (Q1 FY25), up 44% YoY
• Standalone Net Loss After Tax: ₹(670) Lakh vs ₹(1,378) Lakh in Q1 FY25
• Consolidated Net Profit After Tax: ₹396 Lakh vs loss of ₹(1,588) Lakh in Q1 FY25
• Earnings Per Share (Consolidated): ₹0.66 vs ₹(2.59) in Q1 FY25

Exceptional Items:

• Consolidated exceptional income of ₹1,132 Lakh in Q1 FY26, primarily from a settlement with Apotex Inc. (₹858 Lakh) and deferred consideration from prior brand sales (₹274 Lakh).

Segment Performance (Consolidated):

• Vaccines: Revenue ₹11,225 Lakh (up 97.4% YoY); loss before tax narrowed to ₹(425) Lakh from ₹(1,327) Lakh
• Formulations: Revenue ₹5,445 Lakh (down 7.4% YoY); profit before tax ₹1,081 Lakh vs loss of ₹(378) Lakh in Q1 FY25

Balance Sheet / Capital Employed:

• Consolidated capital employed stable at ₹83,664 Lakh vs ₹83,062 Lakh at FY25 end
• Deferred consideration balance reduced to ₹1,837 Lakh from ₹5,436 Lakh in Q1 FY25, recorded as contract liability

Management Commentary:

• Financials prepared on a going concern basis, supported by surplus funds from prior brand sales and new long-term vaccine orders
• No new capex or project expenditure details disclosed in this quarter
• Management highlights improved segment profitability and exceptional income as key drivers of consolidated profitability

Auditor’s Note:

• Independent limited review with unmodified conclusion on standalone and consolidated results; no qualifications or issues reported

Outlook:

• No explicit guidance provided; management emphasizes ongoing realization of deferred consideration and continued focus on standalone profitability and segment growth

This summary captures the key financial and operational developments from Panacea Biotec’s Q1 FY26 results announcement for investment analysis purposes.